Orthocell Ltd. engages in the business of developing and commercializing biological medical devices and cell therapies. Its products include CelGro, which is a naturally derived collagen medical device for soft tissue repair; and Antilogous Tenocyte Implantation for chronic treatment resistant tendon injuries. The company was founded by Paul Frederick Anderson and Ming Hao Zheng on March 21, 2006 and is headquartered in Murdoch, Australia.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company